American Vanguard Corporation
- Open
- 2.19
- Day high
- 2.27
- Day low
- 2.17
- Prev close
- 2.19
- Volume
- 314K
- Mkt cap
- $65M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.4
- P/S
- 0.1
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.2M over the last 3 months (2 open-market buys, 1 sale)
- 🏛Institutions reducing (13F)
American Vanguard Corporation (AVD) is a Basic Materials company listed on NYSE. The stock is down 58% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 1 sale (SEC Form 4).
American Vanguard Corporation (AVD) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AVD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $0.09 | $-0.34 | -477.8% | $117M | -13.5% |
| May 6, 2026 | $-0.06 | $-0.14 | -133.3% | $124M | +3.0% |
| Mar 16, 2026 | $0.28 | $0.06 | -78.6% | $151M | -7.6% |
| Jul 31, 2025 | $-0.11 | $-0.03 | +72.7% | $129M | +1.0% |
| Jun 6, 2025 | $-0.07 | $-0.24 | -242.9% | $116M | -8.8% |
| May 9, 2024 | $0.08 | $0.09 | +12.5% | $135M | -4.8% |
| Mar 14, 2024 | $0.27 | $0.24 | -11.1% | $172M | -0.4% |
| Mar 13, 2023 | $0.08 | $0.13 | +62.5% | $160M | +0.9% |
| May 4, 2022 | $0.20 | $0.32 | +60.0% | $149M | +14.5% |
| Mar 8, 2022 | $0.24 | $0.18 | -25.0% | $159M | +3.6% |
| May 6, 2021 | $0.05 | $0.08 | +60.0% | $116M | +1.0% |
| Mar 11, 2021 | $0.22 | $0.26 | +18.2% | $141M | — |
AVD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 20, 2026 | ROSENBLOOM KEITH Mdirector | Sell | 556,580 | $2.20 |
| Aug 18, 2026 | Macicek Steven Ddirector | Buy | 19,000 | $2.09 |
| Jun 9, 2026 | ROSENBLOOM KEITH Mdirector | Grant | 31,872 | — |
| Jun 8, 2026 | Kaye Douglasofficer: CHIEF EXECUTIVE OFFICER | Buy | 5,000 | $2.50 |
| Jun 8, 2026 | Kaye Douglasdirector, officer: CHIEF EXECUTIVE OFFICER | Grant | 50,000 | $2.51 |
| Jun 8, 2026 | Johnson David` T.officer: See Remarks | Grant | 20,000 | $2.51 |
| Jun 8, 2026 | McDougal Rubin Jdirector | Grant | 31,872 | — |
| Jun 5, 2026 | Macicek Steven Ddirector | Grant | 31,872 | — |
| Jun 5, 2026 | Donnelly Timothy Jofficer: See Remarks | Grant | 20,000 | $2.51 |
| Jun 5, 2026 | DiPaola Michael Josephofficer: Chief Commercial Officer | Grant | 20,000 | $2.51 |
| Jun 5, 2026 | Straley Jaredofficer: SVP Operations & Supply Chain | Grant | 20,000 | $2.51 |
| Jun 5, 2026 | Gottschalk Patrick Edirector | Grant | 31,872 | — |
| Jun 5, 2026 | Bassett Mark Rdirector | Grant | 31,872 | — |
| Jun 5, 2026 | Khosravi Shirinofficer: CHRO | Grant | 20,000 | $2.51 |
| Jun 5, 2026 | Gilliam Nolteanousofficer: SVP Manufacturing | Grant | 20,000 | $2.51 |
Source: AVD SEC Form 4 filings, latest Aug 20, 2026. For informational purposes only — not investment advice.
See the full AVD insider & 13F page →American Vanguard Corporation company profile
Overview
American Vanguard Corporation (NYSE:AVD) is a specialty chemical company founded in 1969 and headquartered in Newport Beach, California. The company has been publicly traded since 1987 and operates as a developer, manufacturer, and marketer of agricultural chemicals and related products. American Vanguard serves agricultural, commercial, and consumer markets both domestically and internationally, focusing on crop protection chemicals, soil health products, and innovative agricultural technologies. The company has evolved from a traditional chemical manufacturer into a more diversified agricultural solutions provider, incorporating biological products and precision agriculture technologies into its portfolio.
Business
American Vanguard operates in the agricultural inputs industry, which provides essential chemicals and technologies that farmers use to protect crops and enhance agricultural productivity. The company's core business revolves around developing, manufacturing, and marketing specialty crop protection chemicals and related agricultural products. The company's primary products include insecticides (chemicals that kill harmful insects), fungicides (products that prevent fungal diseases in crops), herbicides (weed control chemicals), molluscicides (snail and slug control products), and soil fumigants (chemicals that sterilize soil of pests and diseases). These products are formulated in various forms including liquids, powders, and granules to suit different application methods and crop types. Key branded products include Aztec (a corn soil insecticide), Dacthal (a pre-emergence herbicide), and Folex (a cotton defoliant). Beyond traditional chemicals, American Vanguard has expanded into several complementary areas. The company's Green Solutions portfolio focuses on biological and sustainable agricultural products, representing approximately 10-15% of total revenue. The company also operates SIMPAS, a precision agriculture technology platform that enables targeted application of nutrients and crop protection products, helping farmers optimize input usage and potentially reduce environmental impact. The business is organized into three main segments: 1. U.S. Crop Business (approximately 60-65% of revenue) serves row crop farmers with products for corn, soybeans, cotton, and other major crops. 2. U.S. Non-Crop Business (approximately 20-25% of revenue) includes turf and ornamental markets, serving golf courses, landscapers, and consumer markets. 3. International Business (approximately 15-20% of revenue) primarily serves Latin American markets, particularly Brazil, with crop protection products tailored to local agricultural needs.
Revenue model
American Vanguard generates revenue primarily through product sales of its manufactured and formulated agricultural chemicals. The company operates both as a manufacturer of proprietary formulations and as a distributor of third-party products. Revenue comes from selling these products to distributors, retailers, and directly to end-users including farmers, agricultural cooperatives, and commercial applicators. The company's business model involves several revenue streams. Manufacturing and formulation represents the core business, where American Vanguard produces its own branded products with higher margins. Distribution activities involve marketing and selling third-party products alongside proprietary ones, typically generating lower margins but providing broader market coverage. The SIMPAS technology platform generates revenue through equipment sales and ongoing service relationships with farmers. Several factors significantly impact the company's profitability margins. Raw material costs represent a major variable expense, particularly for active ingredients sourced from China and other international suppliers. Supply chain disruptions, as experienced with key products like Aztec and Dacthal, can severely impact sales and margins. Agricultural commodity prices directly influence farmer purchasing power and willingness to invest in crop protection products. When corn, soybean, and cotton prices are high, farmers typically increase their spending on inputs, boosting demand for American Vanguard's products. Seasonal patterns create significant quarterly variation in revenue and cash flow, with spring planting season (Q1-Q2) typically generating the highest sales. Generic competition poses ongoing margin pressure, particularly for older, off-patent products like Folex, where the company must compete primarily on service and formulation quality rather than unique chemistry. Regulatory changes can create both opportunities and threats, as seen with potential dicamba restrictions that could benefit the company's alternative herbicide portfolio, while EPA health concerns led to the voluntary suspension of Dacthal sales.
Competitive moat
American Vanguard operates in a competitive agricultural chemicals industry with limited sustainable competitive advantages. The company's moat is relatively narrow and primarily consists of several modest defensive positions rather than a single strong competitive barrier. The company's specialized formulation expertise provides some differentiation, particularly in developing region-specific products and application methods. American Vanguard's ability to create proprietary formulations of existing active ingredients, such as its ProLease technology for herbicides, offers temporary competitive advantages until competitors develop similar capabilities. Distribution relationships and market presence constitute another modest moat component. The company has established relationships with agricultural distributors, cooperatives, and retailers built over decades of operation. These relationships, combined with technical support and agronomic expertise, create switching costs for customers who value service quality and reliability. The SIMPAS precision agriculture platform represents the company's most promising potential moat, offering a technology-based differentiation that could create customer stickiness through data and service relationships. However, this platform is still in relatively early adoption stages with only 240-250 systems deployed. The company faces significant competitive threats from large multinational agrochemical companies like Bayer, Syngenta, and Corteva, which possess superior research and development resources, broader product portfolios, and stronger financial positions. Generic competition continues to erode margins on older products, while regulatory pressures and environmental concerns create ongoing uncertainty. The company's relatively small size limits its ability to invest heavily in new product development compared to industry giants, making it vulnerable to technological disruption and evolving agricultural practices.
Risks & safety
American Vanguard presents moderate financial risk with several concerning near-term metrics but reasonable longer-term fundamentals. • Liquidity concerns: Cash position of only $11.9 million as of Q3 2024, down from previous quarters, creates potential short-term funding pressure • Debt levels: Debt-to-equity ratio of 0.61, representing manageable but elevated leverage for a cyclical business • Profitability challenges: Negative EBITDA of -$22.7 million in Q3 2024, though this includes one-time Dacthal recall costs of approximately $16 million • Current ratio: 1.89 indicates adequate short-term liquidity to meet current obligations • Valuation metrics: Trading at 0.46x book value suggests potential undervaluation, though negative earnings make traditional P/E ratios meaningless • Seasonal cash flow: Strong Q4 2023 operating cash flow of $87 million demonstrates the business can generate significant cash during peak seasons • Transformation costs: Current losses partially reflect ongoing business transformation investments expected to yield $20 million in annual EBITDA improvements
Recent development
American Vanguard has undergone significant strategic transformation over the past few years, shifting from a traditional chemical manufacturer toward a more diversified agricultural solutions provider. The company launched Project Accelerator in 2023, a comprehensive business transformation initiative targeting $15-20 million in annual EBITDA improvements by 2026 through operational efficiencies, pricing optimization, and organizational restructuring. The company has aggressively expanded its Green Solutions portfolio of biological and sustainable agricultural products, achieving 18% growth in Q3 2024 and 20% year-to-date growth. This strategic pivot addresses growing market demand for environmentally sustainable farming practices and positions the company for evolving regulatory requirements. SIMPAS precision agriculture technology represents another key strategic development, with the company deploying approximately 250 systems and expanding operations into Brazil. This platform enables precise application of nutrients and crop protection products, potentially creating recurring revenue streams and deeper customer relationships beyond traditional product sales. The company has also focused heavily on supply chain resilience following significant disruptions with key products Aztec and Dacthal. Management implemented dual-sourcing strategies for critical raw materials and increased inventory buffers to prevent future supply shortages. However, the company faced a major setback with the voluntary suspension of Dacthal sales due to EPA health concerns, removing approximately $15 million in annual revenue. Recent quarters have been marked by challenging market conditions including agricultural destocking, generic competition pressures, and the costly Dacthal product recall. Despite these headwinds, management maintains confidence in the transformation strategy and expects to achieve 15% adjusted EBITDA margins across agricultural cycles as improvements take effect.
AVD company profile · for informational purposes only — not investment advice.
Track AVD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free